Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study
- PMID: 8021787
- DOI: 10.1016/s0022-3476(94)70122-9
Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study
Abstract
To assess the natural history of optic pathway tumors (OPT) in children with neurofibromatosis type 1 (NF-1), from January 1985 through May 1993 we performed a prospective, longitudinal study of OPT in an unselected population of children with NF-1. Of 227 children with NF-1 seen in a specialty clinic, 176 (77%) underwent neuroimaging. Children in whom tumors were identified were followed closely by both repeated neuroimaging and ophthalmologic examinations to detect tumor growth or visual deterioration. Thirty-three children (19%) were found to have OPT at a median age of 4.2 years. The median age of children who had ophthalmologic complaints was significantly lower than that of children who had no such complaints (1.9 vs 5.3 years; p < 0.001). Although eight tumors were discovered because of ophthalmologic complaints or evidence of precocious puberty, 25 children (76%) were free of symptoms at the time of diagnosis. Twenty-one children (64%) had normal ophthalmologic findings at diagnosis; six children, all with chiasmal tumors, had previously unrecognized decreased visual acuity. Only three children (9%) had evidence of either tumor growth or deteriorating vision after diagnosis; the median duration of neuroimaging follow-up was 2.4 years (range, 0.2 to 7.2 years) and of ophthalmologic examinations 3.4 years (range, 0.2 to 8.1 years). All symptomatic OPT were diagnosed before 6 years of age. We conclude that OPT rarely progress during the next few years in children with NF-1 once the OPT have been discovered. The utility of screening neuroimaging for OPT in symptom-free children with NF-1 appears very limited.
Comment in
-
Screening for optic gliomas in neurofibromatosis type 1: the role of neuroimaging.J Pediatr. 1995 Sep;127(3):507-8. doi: 10.1016/s0022-3476(95)70099-4. J Pediatr. 1995. PMID: 7658289 No abstract available.
Similar articles
-
Precocious puberty in children with neurofibromatosis type 1.J Pediatr. 1995 Mar;126(3):364-7. doi: 10.1016/s0022-3476(95)70449-3. J Pediatr. 1995. PMID: 7869193 Clinical Trial.
-
Optic gliomas in children with neurofibromatosis type 1.J Pediatr. 1989 May;114(5):788-92. doi: 10.1016/s0022-3476(89)80137-4. J Pediatr. 1989. PMID: 2497236
-
Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history.J Pediatr. 1995 Nov;127(5):718-22. doi: 10.1016/s0022-3476(95)70159-1. J Pediatr. 1995. PMID: 7472822
-
Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1.Pediatrics. 1997 Oct;100(4):667-70. doi: 10.1542/peds.100.4.667. Pediatrics. 1997. PMID: 9310522 Review.
-
Intracranial gliomas in neurofibromatosis type 1.Am J Med Genet. 1999 Mar 26;89(1):38-44. doi: 10.1002/(sici)1096-8628(19990326)89:1<38::aid-ajmg8>3.0.co;2-m. Am J Med Genet. 1999. PMID: 10469435 Review.
Cited by
-
Function of the Retinal Pigment Epithelium in Patients With Neurofibromatosis Type 1.Invest Ophthalmol Vis Sci. 2022 Apr 1;63(4):6. doi: 10.1167/iovs.63.4.6. Invest Ophthalmol Vis Sci. 2022. PMID: 35394491 Free PMC article.
-
Brain Tumors in Neurofibromatosis.Curr Treat Options Neurol. 2003 May;5(3):199-206. doi: 10.1007/s11940-003-0010-3. Curr Treat Options Neurol. 2003. PMID: 12670408
-
Recent Updates on Radiation Therapy for Pediatric Optic Pathway Glioma.Brain Tumor Res Treat. 2022 Apr;10(2):94-100. doi: 10.14791/btrt.2022.0003. Brain Tumor Res Treat. 2022. PMID: 35545828 Free PMC article. Review.
-
Children with supratentorial midline pilocytic astrocytomas exhibit multiple progressions and acquisition of neurologic deficits over time.Neurooncol Adv. 2021 Dec 27;4(1):vdab187. doi: 10.1093/noajnl/vdab187. eCollection 2022 Jan-Dec. Neurooncol Adv. 2021. PMID: 35036914 Free PMC article. No abstract available.
-
Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.J Neurosci Res. 2019 Jan;97(1):45-56. doi: 10.1002/jnr.24250. Epub 2018 Apr 28. J Neurosci Res. 2019. PMID: 29704429 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous